α 发射器标记放射性片用于瘤的向α治疗
Patrick A Cieslik1, Björn Wängler1,2,3, Carmen Wängler2,4
1Heidelberg University, Medical Faculty Mannheim, Clinic of Radiology and Nuclear Medicine, Molecular Imaging and Radiochemistry, Theodor-Kutzer-Ufer 1-3, Mannheim 68167, Germany.
Journal of medicinal chemistry
|November 21, 2025
概括
与β-发射体相比,α-发射体放射性提供了优越的瘤治疗方法. 未来的研究必须解决挑战,以充分利用向性α疗法 (TAT) 治疗癌症.
科学领域:
- 核医学是一种核医学.
- 在瘤学瘤学.
- 放射性药物疗法是一种放射性药物疗法.
背景情况:
- 类是核医学中用于诊断和治疗的关键瘤定位剂.
- 从历史上看,贝塔发射体标记是受体特异性癌症治疗的标准.
- 由于更高的治疗效率,正在出现向α-发射器标记的转变.
研究的目的:
- 讨论alpha-emitter放射性在瘤向性alpha疗法 (TAT) 中的优势.
- 识别和突出阻碍阿尔法发射体治疗充分发挥潜力的挑战.
主要方法:
- 关于放射性类药物治疗的当前文献的审查.
- 分析阿尔法发射器对β发射器的优势.
- 识别针对性阿尔法疗法的应用中的挑战.
主要成果:
- 在瘤治疗中,α发射器的治疗效率明显高于β发射器.
- 由于其有利的特性,类作为有效的放射性核酸载体.
- 过渡到α-发射放射性体代表了核医学治疗的重大进步.
结论:
- 使用α-发射放射性的向性α疗法 (TAT) 在癌症治疗方面显示出很大的前景.
- 克服当前的挑战对于充分发挥TAT的潜力至关重要.
- 需要进一步的研究来优化瘤学中的α-发射体放射性的应用.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers
1.4K
Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline...
1.4K
Positron Emission Tomography
6.9K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
6.9K
Types of Radioactivity
19.3K
The most common types of radioactivity are α decay, β decay, γ decay, neutron emission, and electron capture.
Alpha (α) decay is the emission of an α particle from the nucleus. For example, polonium-210 undergoes α decay:
Alpha (α) decay is the emission of an α particle from the nucleus. For example, polonium-210 undergoes α decay:
19.3K
Transducer Mechanism: Enzyme-Linked Receptors
3.8K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
3.8K
![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)

